Background: Pyridoxal 5-phosphate (PLP) is the biologically active form of vitamin B 6 . Clinical studies suggest that low PLP concentrations are an independent risk factor for cardiovascular and other diseases. However, PLP concentrations are not routinely diagnosed because of the lack of a homogeneous, nonradioactive assay. We describe a homogeneous, nonradioactive, enzymatic PLP assay that uses the apo form of the PLPdependent recombinant enzyme, homocysteine-␣,␥-lyase (rHCYase). Methods: PLP was removed from holoenzyme rHCYase by incubation with hydroxylamine to obtain apo-rHCYase. The restoration of enzymatic activity by reconstitution of the holoenzyme was linearly related to the amount of PLP bound to the enzyme. The amplification principle of the assay allowed nanomolar concentrations of PLP to be measured by the conversion (by reconstituted holorHCYase) of millimolar concentrations of homocysteine to H 2 S. N,N-Dibutylphenylenediamine (DBPDA) was used for determination of H 2 S, the combination of which forms a chromophore with high absorbance. The assay was initiated by incubation of 5 L of plasma with apo-rHCYase in a binding buffer for 60 min at 37°C. Homocysteine (2.5 mmol/L) was added to the assay buffer and incubated at 37°C for 20 min. The DBPDA reaction was allowed to progress for 10 min and then read at 675 nm. Results: The PLP enzymatic assay has a lower limit of detection of 5 nmol/L and is linear to 200 nmol/L. The recovery of PLP was 98%. The mean within-and between-run CVs were 9.6% and 12%, respectively. Correlation of 45 samples in the PLP enzymatic assay and the B 6 3 H radioenzymatic assay (American Laboratory Products Co., Ltd.) yielded: y ‫؍‬ 0.9367x ؉ 10.569 (R 2 ‫؍‬ 0.9201).
Pyridoxal 5Ј-phosphate (PLP) 1 is the biologically active form of vitamin B 6 and is involved in numerous metabolic pathways as an enzyme cofactor (1) (2) (3) . Homocysteine (HCY), a risk factor for cardiovascular and other diseases, including Alzheimer disease (4, 5 ) , is converted to cysteine by PLP-dependent transsulfuration enzymes, which condense HCY with serine to form cystathionine and subsequently convert it to cysteine (6 ) . A major cause of homocysteinemia is insufficient intake of vitamin B 6 , vitamin B 12 , and folic acid, which are also necessary for HCY metabolism (7 ) . Clinical studies suggest that vitamin B 6 is independently associated with an increased risk for cardiovascular disease (8 -10 ) , and recent studies have shown that plasma PLP concentrations are significantly decreased in other pathologic conditions, including rheumatoid arthritis (11 ) . High total HCY (tHCY) and low vitamin B 6 plasma concentrations are associated with an increased risk for deep venous thrombosis independent of established risk factors for deep venous thrombosis. The association of low vitamin B 6 concentrations with deep venous thrombosis is also independent of the tHCY concentration (12 ) .
Several methods have been developed for vitamin B 6 measurement. The most common assay for PLP uses activated apo-tyrosine decarboxylase, which requires PLP to convert [1- 14 C]tyrosine to 14 CO 2 , which is then trapped and counted for radioactivity. Other methods include the vitamin B 6 3 H radioenzymatic assay (REA), which is also based on PLP-dependent tyrosine decarboxylase (13) (14) (15) and HPLC (16, 17 ) . These methods are relatively complex and nonhomogeneous and require specialized equipment and materials, including radioactive reagents.
We describe in this report a single-enzyme, nonradioactive, homogeneous assay for PLP that uses the apo form of PLP-dependent, recombinant homocysteine ␣,␥-lyase (rHCYase) cloned from Trichomonas vaginalis (18, 19 ) . The PLP enzymatic assay is simple, rapid, sensitive, and specific and requires only a small volume of plasma.
Materials and Methods
The following materials were obtained from SigmaAldrich: pyridoxal phosphate, pyridoxal, pyridoxamine, pyridoxine, dithiothreitol, sodium bisulfate, d,l-HCY, potassium ferricyanide, and Triton X-100. N,N-Dibutylphenylenediamine (DBPDA) was synthesized in our laboratory. rHCYase was produced in our laboratory (19 ) . The vitamin B 6 3 H REA reagent set was purchased from American Laboratory Products Co., Ltd.
preparation of apo-rHCYase
Hydroxylamine is a carbonyl-specific reagent that reversibly dissociates PLP from the holoenzyme. Holo-rHCYase was treated with 10 mmol/L hydroxylamine in 1.8 mL containing 3.75 g/L protein, 40 L of 100 mmol/L dithiothreitol, and 200 L of 100 mmol/L hydroxylamine phosphate and incubated overnight at 4°C. The PLP-depleted apoenzyme was precipitated with 450 g/L ammonium sulfate and centrifuged at 10 000g for 10 min. The supernatant was discarded, and the pellet was dissolved in 1.0 mL of 20 mmol/L potassium phosphate buffer (pH 7.6) containing 1 mmol/L EDTA and 1 mmol/L dithiothreitol. Gel filtration was then performed with 1.0 mL of the aforementioned solution loaded onto a 1.0 ϫ 10 cm G-25 column. The apoenzyme was eluted with 20 mmol/L potassium phosphate buffer (pH 7.6), and the protein peak was collected as measured at the absorbance at 280 nm. This protein peak contained PLP-depleted rHCYase at 0.1 g/L protein. Trehalose at a final concentration of 1.0 g/L was added as a preservative to the apoenzyme solution, which was stored at Ϫ80°C. determination of plp content in holo-and aporHCYase
The PLP content of holo-and apo-HCYase was determined fluorometrically with a modification of a published procedure (20 ) . In brief, 0.2 mL each of holoenzyme (3.75 g/L) and apoenzyme (1.0 g/L) was added to 0.2 mL of 0.8 mol/L perchloric acid. The samples were then centrifuged at 10 000g for 5 min. The pellet was discarded, and the supernatant was used for HPLC analysis. The mobile phase, consisting of 0.1 mol/L sodium perchlorate and 0.5 g/L sodium bisulfite, was adjusted to pH 7.0 by addition of phosphoric acid and pumped at a flow rate of 1.0 mL/min through a LC-18-DB column. The eluate was assessed for PLP content with a spectrofluorophotometer at an excitation wavelength of 300 nm and an emission wavelength of 400 nm. The detection limit for PLP was 0.5 pmol (20) .
reconstitution of holo-rHCYase
Apo-rHCYase (0.1 g/L) was preincubated at 37°C for 60 min in phosphate buffer (pH 7.6) with 50 mol/L PLP (final concentration). Ten microliters of the sample was diluted in 290 L of phosphate buffer (pH 7.6), and 10 L was used for the enzyme activity assay. Ten microliters of the holo-rHcyase (1.0 g/L) was diluted in 290 L of phosphate buffer (pH 7.6), and 10 L was used for the enzyme activity assay. Enzyme activity was measured with a 3-methyl-2-benzothiazoline hydrazone assay for the keto product of the ␣,␥-elimination reaction (19 ) . The assay was performed in 1 mL of 50 mmol/L phosphate buffer (pH 8.0) and 5 mmol/L d,l-HCY for 10 min at 37°C with various amounts of enzyme. The reaction was stopped by addition of 0.5 mL of 45 mL/L trichloroacetic acid. Supernatant (0.5 mL) was added to 0.5 mL of 0.5 mL/L 3-methyl-2-benzothiazoline hydrazone in 1.0 mL of 1.0 mol/L sodium acetate (pH 5.2) and incubated for 30 min at 50°C. The product was determined spectrophotometrically by the absorbance at 335 nm.
plasma sample preparation
Blood was collected by venipuncture into a Vacutainer Tube (Becton-Dickinson) containing EDTA. After centrifugation, the plasma sample was stored at Ϫ80°C until the time of assay.
plp enzymatic assay protocol 
specificity for plp
To determine the specificity of the PLP enzymatic assay, apo-rHCYase was first incubated with pyridoxal phosphate, pyridoxal, pyridoxamine, and pyridoxine, each at a concentration of 100 nmol/L. The PLP enzymatic assay was then performed with HCY as described above.
reconstitution stability of apo-rHCYase
Twenty microliters of apo-rHCYase (0.1 g/L), stored at 4°C, and 5 L of a 50 nmol/L PLP calibrator were added to 475 L of binding buffer (pH 5.3). After a 60-min preincubation at 37°C, 500 L of assay buffer (pH 8.3) was added to each tube, vortex-mixed, and incubated for 20 min at 37°C. The reconstituted holoenzyme was then used in the PLP enzymatic assay with HCY as described above.
interference Interference in the PLP enzymatic assay was determined by addition of the following substances: bilirubin (ICN), to achieve plasma concentrations of 125 and 250 mol/L; hemoglobin (Sigma) at 2500 and 5000 mg/L; and triglycerides (Sigma) at 3.32 and 6.65 mmol/L. All plasma samples were obtained from three healthy individuals (Table 3) .
Results

principle of the assay
PLP is removed from the rHCYase holoenzyme by incubation with hydroxylamine to obtain apo-rHCYase. The restoration of enzymatic activity by reconstitution of the holoenzyme depends on the amount of PLP bound to rHCYase (Reaction 1):
H 2 S combines with DBPDA to form an absorbance compound (Reaction 2). The absorbance is read at 675 nm: 
specificity for plp reconstitution
We confirmed the absolute dependence of HCYase activity on PLP. Other vitamin B 6 compounds, including pyridoxal, pyridoxamine, and pyridoxine, did not restore any detectable activity to apo-rHCYase.
stability of apo-rHCYase
The apo-rHCYase reconstituted with PLP in 20 mmol/L potassium phosphate buffer (pH 7.6) was stable at 4°C for at least 1 month. The apoenzyme was stable at Ϫ80°C for 1 year.
evaluation of the assay
Linear response. To determine the linear response of the assay, we assayed five different PLP concentrations, 5, 10, 50, 100, and 200 nmol/L, by the present method. As shown in Fig. 1 , the calibration was linear between 5 and 200 nmol/L.
Analytic recovery. The analytic recoveries for PLP added to human pooled serum are shown in Table 1 . Recoveries were 103% at 10 nmol/L, 96% at 50 nmol/L, and 94% at 100 nmol/L, with a mean recovery of 98%.
Precision. The within-assay variation was estimated after three samples, containing 22.4, 77.2, and 125.1 nmol/L PLP, were analyzed in 20 parallel determinations. Each sample was assayed in duplicate. The between-assay variation was determined from 20 successive analytic set-ups that analyzed aliquots from a single sample on 10 different days over a 1-month period. The within-and between-assay mean CVs were 9.6% and 12%, respectively (Table 2) .
Correlation. The concentration of PLP in 45 different human serum samples was measured by the present method and the vitamin B 6 3 H REA method. As shown in Fig. 2 , excellent agreement was observed between the methods by linear regression analysis ( Fig. 2A) , which yielded the equation y ϭ 0.9367x ϩ 10.569 (R 2 ϭ 0.9201), and by a Bland-Altman plot (21 ) of the difference between the results obtained by the two methods as a function of their mean value Ϯ 2 SD (Fig. 2B) .
interference Bilirubin at 125 and 250 mol/L had no appreciable effect on the assay (Table 3 ). Hemoglobin at 2500 mg/L had no appreciable effect, but at 5000 mg/L produced a Ϫ13% change in the result (Table 3 ). Triglycerides at 3.32 and 6.65 mmol/L had a negligible effect on the assay (Table 3) .
Discussion
We report here the first homogeneous, nonradioactive assay for determining vitamin B 6 (PLP) in plasma. Only a single enzyme was necessary in this assay. We used a three-step procedure to prepare apo-rHCYase by use of hydroxylamine phosphate, a carbonyl-specific reagent known to reversibly dissociate PLP from PLP-dependent enzymes (22) (23) (24) (25) . To prevent the apoenzyme from rebinding free PLP, the enzyme was precipitated rapidly with ammonium sulfate to remove free PLP and hydroxylamine phosphate.
We observed that 10 mmol/L citric phosphate buffer (pH 5.3) was more effective for dissociation of PLP and the subsequent apoenzyme reconstitution. The apo-rHCY- ase typically retained 0.5-1.0% of the original enzyme activity, which indicates that a small, residual amount of PLP remained bound to the PLP-free enzyme (26 ) . The apo-rHCYase, however, had lower residual enzyme activity and a high recovery of enzyme activity with PLP. We previously described a simple, single-enzyme assay method for measurement of HCY by modified methylene blue determination of H 2 S (27 ). The PLP method uses the amplification principle of the HCY enzymatic assay, which allows nanomolar concentrations of PLP to be measured, with the signal conversion of millimolar concentrations of HCY to H 2 S. Amplification of the PLP signal is on the order of 10 6 , which enables PLP concentrations as low as 5 nmol/L to be measured.
We observed an excellent correlation between our new method and the vitamin B 6 3 H REA method. The new analytic method may be useful in the diagnosis of vitamin B 6 deficiency in large, population-based studies because PLP appears to be an independent risk factor for cardiovascular and other diseases. We are now developing a fully automated method based on this assay system. A main goal will be to shorten the reconstitution time to further reduce the total assay time.
